The Gemini /DNA platform is presented as an LNP-free route for more stable genetic vaccines and nanomedicines.
Evidence
This platform experiment reports a bifunctional promoter system usable as saRNA or , with freeze-thaw, lyophilization, ambient-storage, payload, expression, safety-profile, manufacturing, and single-dose SARS-CoV-2 vaccine demonstrations.
Caveat
The abstract does not specify human clinical testing, so claims about broad medical and pandemic use remain platform-level rather than proven clinical outcomes.
Simplified
Conventional mRNA vaccines played a crucial role in mitigating the COVID-19 pandemic but remain hampered by inherent instability, transient expression, limited payload capacity, and complex manufacturing, including their reliance on lipid nanoparticle (LNP) encapsulation. To address these challenges, this study describes the Gemini platform, an expression system with a bifunctional eukaryotic-prokaryotic promoter that can be deployed as either a (saRNA) or as a (saDNA) replicon, enabling robust amplification and expression of genetic cargo. Gemini eliminates the requirement for LNPs, exhibits enhanced stability during freeze-thaw cycles and lyophilization, and is compatible with ambient-temperature storage, thereby simplifying production and distribution. It maintains a strong safety profile, supports larger and more complex payloads than conventional mRNA vaccines, and induces prolonged protein expression, as demonstrated by a potent single-dose SARS-CoV-2 Gemini-based vaccine. With rapid, scalable manufacturing and flexibility across saRNA and saDNA formats, Gemini represents a versatile next-generation platform with potential for broad applications in molecular medicine and pandemic preparedness.
Key numbers
98%
Increase in expression (-)
Percentage of cells positive for at day 14 post-injection.
6×
6-fold reduction in expression ()
Reduction in expression from by day 6 compared to day 2.
~3.4 × 10
Integration frequency of
Estimated copies of integrated per cell genome.
Full Text
We can’t show the full text here under this license.
Competing interests: The University of British Columbia is the owner of the intellectual property associated with this study that is licensed to university start-up company, Eyam Health Inc. With the exception of IS, all authors acknowledge financial holdings and professional affiliations or advisory positions with the company; and WAJ acknowledges board membership as CSO.
mRNA Technology